LENALIDOMIDE PLUS HIGH-DOSE VERSUS LOW-DOSE DEXAMETHASONE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC REVIEW

被引：0

作者：

Kupas, K. ^{[1
]}

Kaspar, I. ^{[1
]}

Baecke, V. ^{[2
]}

Weisel, K. ^{[3
]}

机构：

[1] Bristol Myers Squibb, Munich, Germany

[2] Ecker Ecker GmbH, Hamburg, Germany

[3] Univ Tubingen, Tubingen, Germany

来源：

HAEMATOLOGICA | 2017年 / 102卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

E1256

引用

页码：514 / 515

页数：2

共 50 条

[41] Bortezomib in combination with high-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. [J].

Kropff, M ;

Bisping, G ;

Liebisch, P ;

Sezer, O ;

Einsele, H ;

Straka, C ;

Kroeger, N ;

Metzner, B ;

Engelhardt, M ;

Lang, N ;

Hentrich, M ;

Wolf, H ;

von Schilling, C ;

Salwender, H ;

Berdel, WE ;

Kienast, J .

BLOOD, 2005, 106 (11) :716A-716A

[42] Bortezomib or high-dose dexamethasone for relapsed multiple myeloma [J].

Richardson, PG ;

Sonneveld, P ;

Schuster, MW ;

Irwin, D ;

Stadtmauer, EA ;

Facon, T ;

Harousseau, JL ;

Ben-Yehuda, D ;

Lonial, S ;

Goldschmidt, H ;

Reece, D ;

San-Miguel, JF ;

Bladé, J ;

Boccadoro, M ;

Cavenagh, J ;

Dalton, WS ;

Boral, AL ;

Esseltine, DL ;

Porter, JB ;

Schenkein, D ;

Anderson, KC .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (24) :2487-2498

[43] A phase lb multicenter dose escalation study of carfilzomib plus lenalidomide and low-dose dexamethasone in relapsed multiple myeloma - preliminary results [J].

Niesvizky, R. ;

Wang, M. ;

Bensinger, B. ;

Vallone, M. ;

Gutierrez, A. A. ;

Kauffman, M. .

EJC SUPPLEMENTS, 2009, 7 (02) :569-569

[44] Dose-escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (Dex) (CRd) in relapsed/refractory multiple myeloma (R/R MM) [J].

Bensinger, W. ;

Wang, M. ;

Orlowski, R. Z. ;

Alsina, M. ;

Martin, T. ;

Singhal, S. ;

Gabrall, N. Y. ;

Vallone, M. ;

Kauffman, M. ;

Niesvizky, R. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

[45] LENALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE IN RELAPSE/ REFRACTORY MULTIPLE MYELOMA: A RETROSPECTIVE STUDY [J].

Firatli-Tuglular, T. ;

Noyan-Atalay, F. ;

Eser, A. ;

Toptas, T. ;

Pepedil, F. ;

Kaygusuz-Atagunduz, I. ;

Adiguzel, C. .

HAEMATOLOGICA, 2013, 98 :614-615

[46] Efficacy and safety of low-dose lenalidomide plus dexamethasone in patients with relapsed or refractory POEMS syndrome [J].

Cai, Qian-Qian ;

Wang, Chen ;

Cao, Xin-Xin ;

Cai, Hao ;

Zhou, Dao-Bin ;

Li, Jian .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 95 (04) :325-330

[47] Is bortezomib superior to high-dose dexamethasone for the treatment of relapsed multiple myeloma? [J].

Robert Z Orlowski .

Nature Clinical Practice Oncology, 2006, 3 :16-17

[48] Is bortezomib superior to high-dose dexamethasone for the treatment of relapsed multiple myeloma? [J].

Orlowski, RZ .

NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (01) :16-17

[49] Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies [J].

Richardson, Paul G. ;

Perrot, Aurore ;

San-Miguel, Jesus ;

Beksac, Meral ;

Spicka, Ivan ;

Leleu, Xavier ;

Schjesvold, Fredrik ;

Moreau, Philippe ;

Dimopoulos, Meletios A. ;

Huang, Jeffrey S. Y. ;

Minarik, Jiri ;

Cavo, Michele ;

Prince, H. Miles ;

Mace, Sandrine ;

Malinge, Laure ;

Dubin, Franck ;

Morisse, Mony ;

Anderson, Kenneth C. .

BLOOD, 2022, 140

[50] Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): final overall survival analysis [J].

Richardson, Paul ;